Biotechnology

A novel topical gel that boosts cellular energy is now in late-stage trials, offering new hope for healing the chronic wounds of diabetic foot ulcers.

New MD Andreas Goppelt brings a bold M&A and digital transformation agenda to OrphaCare, aiming to reshape rare disease patient care globally.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

YPrime's new AI Calculation Engine lets researchers use plain language to build complex trial logic, aiming to slash setup times and boost data accuracy.

A new partnership brings sustainable, wash-free lab tech to the GCC & MENA, aiming to accelerate drug discovery in the world's fastest-growing life-science market.

A Dubai hospital pioneers a one-time gene therapy for an adult with SMA, offering new hope to a patient population previously left with limited options.

A new cell-free therapy, Ultrasome™, shows a 93% response rate in a pilot study, offering a scalable, regenerative solution for millions with knee pain.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

Neurogene bets on a direct-to-brain delivery method for its Rett syndrome gene therapy, arguing the established surgical technique offers superior results.

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.

Pharma manufacturer Mikart cuts the ribbon on a new Atlanta HQ while boosting bottling capacity by 50%, tackling industry demand and fueling local growth.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.

With gonorrhea becoming increasingly resistant to antibiotics, a new $2.6M grant fuels the development of a promising preventative vaccine platform.

Biotech firm Tr1X unveils promising data for its novel cell therapies, offering a scalable new approach to treating autoimmune diseases like MS and GvHD.

Dyno Therapeutics is using AI to design 'smart' viral vectors, promising safer, more effective treatments for untreatable genetic diseases.

Biotech firm Cellectis presents a new epigenetic platform that silences genes without cutting DNA, a potentially safer approach for cancer and liver disease.